# EDGAR Filing Document

**Accession Number:** 0001477845
**File Stem:** 0001104659-25-091784
**Filing Date:** 2025-9
**Character Count:** 3085
**Document Hash:** 6b79c0221e825bd35dadbc6b697d4f86
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-091784.hdr.sgml**: 20260224

**ACCESSION NUMBER**: 0001104659-25-091784

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250919

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Annovis Bio, Inc.
- **CENTRAL INDEX KEY:** 0001477845
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 262540421
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 101 LINDENWOOD DRIVE, SUITE 225
- **CITY:** MALVERN
- **STATE:** PA
- **ZIP:** 19355
- **BUSINESS PHONE:** 484-875-3192

**MAIL ADDRESS:**
- **STREET 1:** 101 LINDENWOOD DRIVE, SUITE 225
- **CITY:** MALVERN
- **STATE:** PA
- **ZIP:** 19355

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** QR Pharma, Inc.
- **DATE OF NAME CHANGE:** 20091202

Via EDGAR

September 19, 2025

Ms. Jenn Do and Ms. Vanessa Robertson<br> U.S. Securities & Exchange Commission

Division of Corporation Finance

Office of Life Sciences<br> 100 F Street, NE<br> Washington, D.C. 20549

Re: Annovis Bio, Inc.<br> Form 10-K for the fiscal year ended December 31, 2024<br> Filed March 21, 2025<br> File No. 001-39202

Dear Ms. Do and Ms. Robertson:

Annovis Bio, Inc. (the "Company") is in receipt of the Staff's letter dated September 4, 2025 (the "Staff's Letter") regarding the Company's Annual Report on Form 10-K (the "Form 10-K"). Based on my telephone conversation with Ms. Do on September 15, 2025, the Staff requested, and the Company hereby agrees that, in future filings, it will provide narrative disclosure, on a going-forward basis only (no prior period comparison) regarding the breakdown of research and development expenses between the Alzheimer's study and the Parkinson's study. In addition, the filings will continue to show the breakdown as reported in previous filings, Exhibit A.

Please contact me at (610) 880-8485 or by email at maccecchini@annovisbio.com if you have any additional questions.

Sincerely,

![](tm2526166d1_correspimg01.jpg)

Maria Maccecchini

President and Chief Executive Officer

**EXHIBIT A**

**Table from Annovis Bio 2024 10-K**

---

| | | | |
|:---|:---|:---|:---|
|  | **Year Ended** | **Year Ended** | |
|  | **December 31,** | **December 31,** | |
|  | **2024** | **2023** |<br>**Change** |
|  | **(in thousands)** | **(in thousands)** | **(in thousands)** |
| **Operating expenses:** |  |  |  |
| &nbsp;&nbsp;&nbsp;Research and development | $19995 | $38791 | $(18796) |
| &nbsp;&nbsp;&nbsp;General and administrative | 6699 | 6244 | 455 |
| Total operating expenses | 26694 | 45035 | (18341) |
| **Other income (expense):** |  |  |  |
| &nbsp;&nbsp;&nbsp;Interest income | 332 | 668 | (336) |
| &nbsp;&nbsp;&nbsp;Other financing costs | (1853) |  | (1853) |
| &nbsp;&nbsp;&nbsp;Change in fair value of warrants | 3626 | (11837) | 15463 |
| Other income (expense), net | 2105 | (11169) | 13274 |
| **Net loss** | $24589 | $56204 | $(31615) |

---